1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22093
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDerdemezis, C.en
dc.contributor.authorFilippatos, T.en
dc.contributor.authorTselepis, A.en
dc.contributor.authorMikhailidis, D.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T19:21:18Z-
dc.date.available2015-11-24T19:21:18Z-
dc.identifier.issn1744-7666-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22093-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAnticholesteremic Agents/*pharmacologyen
dc.subjectAzetidines/*pharmacologyen
dc.subjectCholesterol/blooden
dc.subjectCholesterol, LDL/blooden
dc.subjectDrug Therapy, Combinationen
dc.subjectDyslipidemias/*drug therapy/physiopathologyen
dc.subjectFemaleen
dc.subjectHeptanoic Acids/pharmacologyen
dc.subjectHumansen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNicotinamide Phosphoribosyltransferase/blood/*drug effectsen
dc.subjectPilot Projectsen
dc.subjectPyrroles/pharmacologyen
dc.titleEffects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1517/14656566.9.11.1829-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/18627322-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.1517/14656566.9.11.1829-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2008-
heal.abstractINTRODUCTION: Ezetimibe inhibits intestinal absorption of cholesterol and lowers circulating low-density lipoprotein cholesterol levels. Visfatin is a novel adipokine, which may be implicated in the atherosclerotic process. OBJECTIVE: The aim of this study was to explore the possible association between ezetimibe administration and serum visfatin concentrations. METHODS: Patients (n = 30) with primary dyslipidemia and another 30 who failed to reach their assigned low-density lipoprotein cholesterol target on atorvastatin therapy (20 mg/day) were included in the study. All participants were given ezetimibe at 10 mg/day for 12 weeks. RESULTS: At baseline the visfatin levels correlated significantly with the total cholesterol (r = 0.61 and p < 0.01) and low-density lipoprotein cholesterol (r = 0.51 and p < 0.01) levels in the statin pretreatment group. Furthermore, in the statin group the post-treatment levels of visfatin and low-density lipoprotein cholesterol were significantly correlated (r = 0.57 and p < 0.01). The serum visfatin concentrations did not change significantly in either the monotherapy or statin pretreatment groups or in subgroups divided according to the baseline lipid variables. In both the ezetimibe monotherapy and ezetimibe plus atorvastatin groups the effect of ezetimibe on the lipid variables depended on the baseline lipid values. The low-density lipoprotein cholesterol:high density lipoprotein cholesterol ratio was consistently improved by ezetimibe in all groups or subgroups. CONCLUSIONS: Ezetimibe did not alter serum visfatin concentrations, either when administered as monotherapy or combined with a statin. Future studies investigating the effect of ezetimibe on visfatin levels need to include groups of patients with distinct lipid characteristics.en
heal.journalNameExpert Opin Pharmacotheren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons